Key Questions RAS Can Help You Answer

  • What is the current solid tumor clinical development landscape?

  • What are the key market impacting events?

  • What´s the strategy of major Oncology players?

  • What´s the positioning and strategy for a molecule of interest?

  • What are the upcoming innovation waves? What are the opportunities created by them?

  • What´s the current state-of-the-art in cancer biomarkers?

  • How to keep pace with the regulatory policies & payer positions across geographies?

  • What drug candidates/ companies are suitable for partnering or in-licensing for oncology therapeutics?

Featured Insights

August 16, 2018 / infographics, Oncology

Evolution In EGFRM+ Lung Cancer

Interest in the EGFR Lung cancer space initially started with the isolation of Epidermal growth factor (EGF) gene by Stanley Cohen in 1962 as a protein extracted from the mouse submaxillary gland that accelerated incisor eruption. Therefore, it was originally termed ‘tooth-lid factor’, but was later renamed EGF because it stimulated the proliferation of epithelial cells. Since then substantial progress has been made against lung cancer over the last two decades. Research has also powered the emergence of new targeted treatments which are helping patients live a longer and higher quality life after a lung cancer diagnosis. This infographic allows the reader to dwell deeper and look closely into the history of discovery, evolution and advancements pertaining to EGFR lung cancer space.
Read More
June 4, 2018 / ASCO18, infographics, Oncology

Major Milestones in Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This infographic highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.
Read More
May 25, 2018 / Featured Insights, Oncology

Nanotechnology in Drug Discovery and Design

This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
Read More
July 18, 2017 / Biosimilars, Featured Insights, Oncology

Oncology Biosimilar Competitive Dynamics

This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.
Read More

Read Our Blogs

June 2, 2018
Gastrointestinal cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers

Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the […]
June 2, 2018
Breast cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Breast Cancer

Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had […]
September 11, 2017
Targetted therapy

Anti-PD1 and PD-L1 Agents in Development

Distribution of Anti Pd-1 / Anti PD-L1 by Phase Related Post Major Milestones In Cancer Research Top ASCO 2018 Abstracts To Watch Out For In Lymphoma Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers
July 17, 2017
clinical_dev_biosimilar

Ongoing Biosimilar Clinical Development in Oncology

As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute […]
June 1, 2017

Journey through ASCO 2015 to 2017

In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be […]
May 31, 2017

Glioblastoma Multiforme Abstracts – RAS Viewpoint

An aggressive malignancy, Glioblastoma is an indication with one of the highest level of unmet need in oncology. Currently, Avastin and Temozolomide dominates the market.  With GBM market estimated to reach $3.3B (G7 market) by 2024 (Globaldata), companies are trying out novel approaches. GBM pipeline is characterized by active early […]

What would you like to know?